08:00 , Nov 6, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Inhalable micelles expressing a lung-targeting peptide for delivery of therapies to treat pulmonary arterial hypertension (PAH) In vitro and mouse studies suggest lung-targeted peptide-micelle conjugates...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Mdm2 p53 binding protein homolog (MDM2; HDM2); p53 Mouse and in vitro studies have identified an MDM2 inhibitor that could help treat breast...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

Oral interferon-alpha lozenges: Phase II data

Vita's CytoPharm Inc. subsidiary and Amarillo reported data from a double-blind, Taiwanese Phase II trial in 169 patients with HCV genotype 1b infection showing that there were no differences in virologic relapse rates, the primary...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Company News

Amarillo infectious, inflammation news

Amarillo will open its Asia Operations Center in Taipei, Taiwan, to explore new business opportunities in Asia. The center will introduce healthcare products and technologies from the U.S. into Asian markets, seek licensing opportunities in...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Company News

Amarillo management update

Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo, Texas   Business: Autoimmune, Infectious, Inflammation   Hired: Stephen Chen, a director, as chairman and CEO; he replaces Joseph Cummins, who remains as president and will become COO  ...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Oral interferon-alpha lozenges: Phase II start

This quarter, Vita's CytoPharm Inc. subsidiary and Amarillo will begin a double-blind, placebo-controlled, Taiwanese Phase II trial to compare 150 IU oral interferon-alpha lozenges twice daily plus 75 mg oral Tamiflu oseltamivir twice daily for...
08:00 , Mar 7, 2011 |  BC Week In Review  |  Financial News

Amarillo proposes follow-on

Amarillo Biosciences Inc. (OTCBB:AMAR), Amarillo, Texas   Business: Autoimmune, Infectious, Inflammation   Date announced: 3/1/11   Type: Follow-on   To be raised: Up to $500,000   Shares: 10 million   Price: $0.05   Note: The...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

Oral interferon-alpha lozenges: Completed Phase II enrollment

Vita's CytoPharm Inc. subsidiary completed enrollment of 165 patients in a double-blind, placebo-controlled, Taiwanese Phase II trial evaluating 500 and 1,500 units/day oral interferon-alpha lozenges for 24 weeks. CytoPharm has rights to develop Amarillo's low-dose...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

Oral interferon-alpha lozenges: Final Phase II data

Final data from a double-blind, Australian Phase II trial in 200 healthy volunteers showed that once-daily oral interferon-alpha lozenges for 16 weeks missed the primary endpoint of significantly reducing the incidence of influenza-like illness vs....
07:00 , Mar 15, 2010 |  BC Week In Review  |  Clinical News

Oral interferon-alpha lozenges: Phase III start

This month, Intas will begin a double-blind, placebo-controlled, Indian Phase III trial to evaluate oral interferon-alpha lozenges in up to 520 patients with influenza-like symptoms. Intas has Indian and Nepalese rights to Amarillo's oral interferon-alpha...